Impact of pharmaceutical industry involvement in the external review of clinical practice guidelines-A case study

被引:2
|
作者
Bartelmann, Katharina
Gaskins, Matthew
Dressler, Corinna
Nast, Alexander
机构
[1] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergy, Div Evidence Based Med DEBM, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
关键词
clinical practice guideline; dermatology; external review; pharmaceutical industry; quality; S3; GUIDELINE; ACNE;
D O I
10.1111/jep.13166
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Rationale and aim External review is important when developing clinical practice guidelines. Involving pharmaceutical companies may influence guideline recommendations in their favour and is therefore controversial. Our study aimed to measure stakeholder participation in the external review of the 2016 European acne guideline and assess the extent to which comments submitted by pharmaceutical companies suggested changes favouring their own products. Methods Retrospective, partially blinded case study using qualitative analysis of comments submitted during external review. Results Four stakeholder groups participated in the review: pharmaceutical company representatives (five out of five invited), professional association members (2/222), journal reviewers (n = 2), and visitors to the project website (n = 1). Of 78 comments submitted, 48 were from company representatives, 24 from journal reviewers, and six from others. Each comment suggested one change to the guideline. Of the comments submitted by companies, 41.7% related to "writing or formatting," 16.7% to "presentation of results," 12.5% to "background information for main recommendations," and 12.5% to the "strength of treatment recommendation". In 54.2% (26/48) of these comments, a change was suggested that put the companies' own products in a more positive light. Five of these changes were implemented by the guideline authors in the way suggested by the company representatives. Conclusion Participation of professional societies, patients, and the general public in the external review of the 2016 European acne guideline was unacceptably low. This is in concordance with reports of low participation of these groups in other European dermatology guidelines. While involving the pharmaceutical industry in the review substantially increased the number of comments received, many of these sought changes that would have put companies' own products in a more favourable light. Our findings underscore the need to manage reviewer comments in a robust and transparent fashion. Solutions to encourage participation of all relevant stakeholders are needed.
引用
下载
收藏
页码:718 / 727
页数:10
相关论文
共 50 条
  • [21] Organizing for external technology commercialization: evidence from a multiple case study in the pharmaceutical industry
    Bianchi, Mattia
    Chiaroni, Davide
    Chiesa, Vittorio
    Frattini, Federico
    R & D MANAGEMENT, 2011, 41 (02) : 120 - 137
  • [22] The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases
    Roach, Meaghan
    Land, Natalie
    Hernandez, Jennifer
    Rau, Reina
    Chou, Jacquelyn W.
    Hickson, Stacey S.
    Rollmann, Danielle F.
    Maclean, J. Ross
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 2024
  • [23] Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines-A Scoping Review
    Chourasia, Prabal
    Maringanti, Babu Sriram
    Edwards-Fligner, Morgan
    Gangu, Karthik
    Bobba, Aniesh
    Sheikh, Abu Baker
    Shekhar, Rahul
    VACCINES, 2023, 11 (01)
  • [24] Metrology in Pharmaceutical Industry - A Case Study
    Yuvamoto, Priscila D.
    Fermam, Ricardo K. S.
    Nascimento, Elizabeth S.
    8TH BRAZILIAN CONGRESS ON METROLOGY (METROLOGIA 2015), 2016, 733
  • [25] Impact of clinical practice guidelines on the clinical microbiology laboratory
    Gilligan, PH
    JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (04) : 1391 - 1395
  • [26] Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review
    Pokorny, Adrian M. J.
    Fabbri, Alice
    Bero, Lisa A.
    Moynihan, Ray
    Mintzes, Barbara J.
    BRITISH JOURNAL OF CANCER, 2022, 126 (01) : 144 - 161
  • [27] Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review
    Adrian M. J. Pokorny
    Alice Fabbri
    Lisa A. Bero
    Ray Moynihan
    Barbara J. Mintzes
    British Journal of Cancer, 2022, 126 : 144 - 161
  • [28] Transparency of industry payments needed in clinical practice guidelines
    Vassar, Matt
    Bibens, Michael
    Wayant, Cole
    BMJ EVIDENCE-BASED MEDICINE, 2019, 24 (01) : 8 - 9
  • [29] THE STRATEGIC IMPACT OF STAKEHOLDERS' PERCEPTIONS: A SINGLE CASE STUDY FROM THE PHARMACEUTICAL INDUSTRY
    Sachs, Sybille
    Schmitt, Ruth
    Groth, Hans
    PROCEEDINGS OF THE NINETEENTH ANNUAL MEETING OF THE INTERNATIONAL ASSOCIATION FOR BUSINESS AND SOCIETY, 2008, 19 : 441 - 452
  • [30] Guidelines for Assessing the Performance of Statisticians Involved in Clinical Research in the Pharmaceutical Industry
    Alan Phillips
    Drug information journal : DIJ / Drug Information Association, 1999, 33 (2): : 427 - 433